Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxaneยฎ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
- Conditions
- Endometrial Clear Cell AdenocarcinomaRecurrent Uterine Corpus CancerStage IIIA Uterine Corpus Cancer AJCC v7Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaStage IVA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Endometrial Serous AdenocarcinomaStage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Biological: BevacizumabDrug: CarboplatinOther: Laboratory Biomarker AnalysisDrug: IxabepiloneDrug: PaclitaxelDrug: Temsirolimus
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 349
- Registration Number
- NCT00977574
- Locations
- ๐บ๐ธ
Henry Ford Health Warren Hospital, Warren, Michigan, United States
๐บ๐ธSaint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
๐บ๐ธMayo Clinic in Arizona, Scottsdale, Arizona, United States
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 149
- Registration Number
- NCT00976573
- Locations
- ๐บ๐ธ
Cancer Center of Kansas-Independence, Independence, Kansas, United States
๐บ๐ธMinnesota Oncology - Woodbury, Woodbury, Minnesota, United States
๐บ๐ธFrank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer
- Conditions
- Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT00976677
- Locations
- ๐บ๐ธ
Illinois CancerCare-Havana, Havana, Illinois, United States
๐บ๐ธMason District Hospital, Havana, Illinois, United States
๐บ๐ธAbramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT00974584
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT00971841
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00971945
- Locations
- ๐ฏ๐ต
Local Institution, Toshima-ku, Tokyo, Japan
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT00971867
- Locations
- ๐ฏ๐ต
Local Institution, Tochigi, Japan
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
- Conditions
- CervicalOvarianLungBreastRenal
- Interventions
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00972205
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer
- Conditions
- Ovarian Cancer
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Russian Academy of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT00964626
- Locations
- ๐ท๐บ
Russian Academy of Medical Sciences Cancer Research Center, Moscow, Russian Federation
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT00960960
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.